Grace Gorecki
Grace Gorecki has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Lan G. Coffman
Womens Cancer Research Center at UPMC Hillman Cancer Center and Magee Women’s Research Institute, Pittsburgh, PA
12 shared publications - Tullia C. Bruno
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
11 shared publications - Amal Taher Elhaw
Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, USA
10 shared publications - Ananya K. Britt
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
10 shared publications - Brian Robert Isett
Cancer Bioinformatics Services, Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
10 shared publications - Ester Goldfeld
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
10 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by MDPI AG in Preprints.org
Concurrent Chemoradiation in Locally Advanced Lung Cancer with Cisplatin–Etoposide or Carboplatin–Paclitaxel: An Institutional Analysis
Concurrent chemoradiation (cCRT) is standard for unresectable, locally advanced non–small cell lung cancer (NSCLC), but the preferred concurrent chemotherapy backbone is uncertain. Cisplatin–etoposide (EP) and weekly carboplatin–paclitaxel (PC) are commonly used. Background/Objectives: Retrospective single-institution cohort of adults with histologically confirmed, inoperable AJCC stage II–III NSCLC treated 2015–2023 with definitive thoracic radiation plus concurrent EP or PC. Methods: We collected clinical characteristics, treatment completion, best radiographic response, adverse events (AEs), progression, and death. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints were overall response rate (ORR) and AEs. Kaplan–Meier survival estimates were generated and compared using log-rank testing; hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: Among 177 patients (EP, n = 43; PC, n = 134), stage III disease comprised 91% in the EP cohort and 90% in the PC cohort. ORR favored EP (63% vs 52%), and primary progressive disease as best response was less frequent with EP (7% vs 21%, p = 0.04). Median PFS was 48.07 vs 14.93 months (HR 0.65, 95% CI 0.43–0.90; p = 0.05). Median OS numerically favored EP (76.97 vs 34.60 months; HR 0.70, 95% CI 0.44–1.12; p = 0.17). Any-grade AEs occurred at similar rates (34.9% vs 34.3%), whereas grade 3–4 AEs were more frequent with EP (25.6% vs 9.7%; p = 0.02). Conclusion: EP-based cCRT was associated with longer PFS and higher grade 3–4 toxicity than PC; findings support individualized selection and need validation, especially in the immunotherapy era.
- 22 April 2026
- Published by MDPI AG in Preprints.org
Open AccessConcurrent Chemoradiation in Locally Advanced Lung Cancer with Cisplatin–Etoposide or Carboplatin–Paclitaxel: An Institutional Analysis
Concurrent chemoradiation (cCRT) is standard for unresectable, locally advanced non–small cell lung cancer (NSCLC), but the preferred concurrent chemotherapy backbone is uncertain. Cisplatin–etoposide (EP) and weekly carboplatin–paclitaxel (PC) are commonly used. Background/Objectives: Retrospective single-institution cohort of adults with histologically confirmed, inoperable AJCC stage II–III NSCLC treated 2015–2023 with definitive thoracic radiation plus concurrent EP or PC. Methods: We collected clinical characteristics, treatment completion, best radiographic response, adverse events (AEs), progression, and death. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints were overall response rate (ORR) and AEs. Kaplan–Meier survival estimates were generated and compared using log-rank testing; hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: Among 177 patients (EP, n = 43; PC, n = 134), stage III disease comprised 91% in the EP cohort and 90% in the PC cohort. ORR favored EP (63% vs 52%), and primary progressive disease as best response was less frequent with EP (7% vs 21%, p = 0.04). Median PFS was 48.07 vs 14.93 months (HR 0.65, 95% CI 0.43–0.90; p = 0.05). Median OS numerically favored EP (76.97 vs 34.60 months; HR 0.70, 95% CI 0.44–1.12; p = 0.17). Any-grade AEs occurred at similar rates (34.9% vs 34.3%), whereas grade 3–4 AEs were more frequent with EP (25.6% vs 9.7%; p = 0.02). Conclusion: EP-based cCRT was associated with longer PFS and higher grade 3–4 toxicity than PC; findings support individualized selection and need validation, especially in the immunotherapy era.
- Open Access
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Age-Related Immune Toxicity and Treatment Outcomes in Triple-Negative Breast Cancer Treated with Pembrolizumab
Purpose: Tolerability and completion of pembrolizumab with neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) varies across age groups. We evaluated age-related patterns in immune-related adverse events (irAEs), pembrolizumab exposure, and clinical outcomes in TNBC patients treated with the KEYNOTE-522 regimen.Methods: We retrospectively analyzed TNBC patients treated with neoadjuvant ± adjuvant pembrolizumab from 2020–2025 at a multicenter healthcare network. Patients were stratified by median age (53 years), with a prespecified sensitivity analysis at 65 years. We compared irAE incidence and severity, treatment completion, pathologic complete response (pCR), event-free survival, and overall survival (OS) using Kaplan–Meier analysis and univariable Cox regression.Results: Among 125 patients, 36.8% developed an irAE, and 15.2% experienced grade ≥3 events. Patients <53 years experienced more irAEs (51% vs. 31%; p = 0.03), developed toxicity earlier (mean 5.7 vs. 7.2 cycles), and required more corticosteroid therapy (36% vs. 18%; p = 0.04). This association was consistent in the sensitivity analysis (odds ratio 3.63, 95% confidence interval [CI] 1.43–9.06, p = 0.006). Despite reduced pembrolizumab exposure, pCR was similar across age groups (72% vs. 73%; p = 0.8). Completion of adjuvant pembrolizumab was associated with improved OS overall (hazard ratio 0.17, 95% CI 0.04–0.75), with a trend toward older patients benefiting more.Conclusion: Younger patients experienced more frequent and earlier irAEs leading to treatment discontinuation yet achieved comparable pCR rates. Older patients were more likely to complete the full regimen with a trend toward improved survival with treatment completion. Age-adapted immunotherapy strategies in early-stage TNBC should be explored.
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAge-Related Immune Toxicity and Treatment Outcomes in Triple-Negative Breast Cancer Treated with Pembrolizumab
Purpose: Tolerability and completion of pembrolizumab with neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) varies across age groups. We evaluated age-related patterns in immune-related adverse events (irAEs), pembrolizumab exposure, and clinical outcomes in TNBC patients treated with the KEYNOTE-522 regimen.Methods: We retrospectively analyzed TNBC patients treated with neoadjuvant ± adjuvant pembrolizumab from 2020–2025 at a multicenter healthcare network. Patients were stratified by median age (53 years), with a prespecified sensitivity analysis at 65 years. We compared irAE incidence and severity, treatment completion, pathologic complete response (pCR), event-free survival, and overall survival (OS) using Kaplan–Meier analysis and univariable Cox regression.Results: Among 125 patients, 36.8% developed an irAE, and 15.2% experienced grade ≥3 events. Patients <53 years experienced more irAEs (51% vs. 31%; p = 0.03), developed toxicity earlier (mean 5.7 vs. 7.2 cycles), and required more corticosteroid therapy (36% vs. 18%; p = 0.04). This association was consistent in the sensitivity analysis (odds ratio 3.63, 95% confidence interval [CI] 1.43–9.06, p = 0.006). Despite reduced pembrolizumab exposure, pCR was similar across age groups (72% vs. 73%; p = 0.8). Completion of adjuvant pembrolizumab was associated with improved OS overall (hazard ratio 0.17, 95% CI 0.04–0.75), with a trend toward older patients benefiting more.Conclusion: Younger patients experienced more frequent and earlier irAEs leading to treatment discontinuation yet achieved comparable pCR rates. Older patients were more likely to complete the full regimen with a trend toward improved survival with treatment completion. Age-adapted immunotherapy strategies in early-stage TNBC should be explored.
- Open Access
- 1 January 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 13
HER2-directed therapy in metastatic vulvar empd—a report of two cases and narrative review
Extramammary Paget’s disease (EMPD) is a rare malignancy of the skin arising in apocrine gland-rich areas, most commonly the vulva, scrotum, and perianal region. Often misdiagnosed due to resemblance to benign dermatologic conditions, EMPD presents diagnostic and therapeutic challenges. While localized disease usually has a favorable prognosis after surgery, metastatic EMPD is rare, with poor outcomes and limited options. Recent molecular profiling has identified human epidermal growth factor receptor 2 (HER2) overexpression as a potential therapeutic target. We present a clinical series of HER2-positive EMPD treated with targeted therapies and review the literature to assess their role in disease control and outcomes. We report two cases of metastatic HER2-amplified vulvar EMPD treated with HER2-directed agents, including trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), and integrate our findings into a narrative review of reported cases. Both patients achieved clinical benefit from HER2-targeted therapy with disease control across sequential regimens. We describe one of the first documented real-world cases of vulvar EMPD treated with T-DXd, showing a meaningful clinical response. HER2-positive metastatic vulvar EMPD may respond to targeted therapy, and T-DXd appears promising for disease control. Molecular HER2 testing should be incorporated into the diagnostic workup to guide therapy selection in this rare malignancy.
- 1 January 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 13
Open AccessHER2-directed therapy in metastatic vulvar empd—a report of two cases and narrative review
Extramammary Paget’s disease (EMPD) is a rare malignancy of the skin arising in apocrine gland-rich areas, most commonly the vulva, scrotum, and perianal region. Often misdiagnosed due to resemblance to benign dermatologic conditions, EMPD presents diagnostic and therapeutic challenges. While localized disease usually has a favorable prognosis after surgery, metastatic EMPD is rare, with poor outcomes and limited options. Recent molecular profiling has identified human epidermal growth factor receptor 2 (HER2) overexpression as a potential therapeutic target. We present a clinical series of HER2-positive EMPD treated with targeted therapies and review the literature to assess their role in disease control and outcomes. We report two cases of metastatic HER2-amplified vulvar EMPD treated with HER2-directed agents, including trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), and integrate our findings into a narrative review of reported cases. Both patients achieved clinical benefit from HER2-targeted therapy with disease control across sequential regimens. We describe one of the first documented real-world cases of vulvar EMPD treated with T-DXd, showing a meaningful clinical response. HER2-positive metastatic vulvar EMPD may respond to targeted therapy, and T-DXd appears promising for disease control. Molecular HER2 testing should be incorporated into the diagnostic workup to guide therapy selection in this rare malignancy.
- Open Access
Prognostic Value of Lymphoid Infiltration and Aggregation in Cervical Cancer
Background/objectives: Understanding the immune landscape in cervical cancer is critical to the development of improved therapeutics. This study investigated the immune microenvironment in early-stage cervical cancer with a focus on B and T cell immune aggregates, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLSs). Methods: Using multispectral imaging, we interrogated a cohort of patients with clinical stage I squamous or adenocarcinoma of the cervix with a focus on T and B cell spatial location and organization. Despite early-stage disease, recurrence was common at 37%, highlighting the need to identify patients at high risk for recurrence. Results: We demonstrated that high CD8+ T cell infiltration correlated significantly with improved overall survival (OS), particularly in patients with adenocarcinoma histology. CD8+ T cells colocalized with B cells, suggesting the formation of a more sophisticated cellular neighborhood, i.e., TLS, which has prognostic benefit in other solid tumors. CXCL13, a chemokine associated with TLS formation, correlated with improved recurrence-free survival. The combination of high CXCL13 and lymphoid structures correlated with improved OS. However, most immune structures in cervical cancer were lymphoid aggregates (LAs) that lack features of more developed TLS, such as high endothelial venules (HEVs) and germinal centers (GCs), highlighting a lack of full immune activation in this microenvironment. Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Conclusions: Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.
Open AccessPrognostic Value of Lymphoid Infiltration and Aggregation in Cervical Cancer
Background/objectives: Understanding the immune landscape in cervical cancer is critical to the development of improved therapeutics. This study investigated the immune microenvironment in early-stage cervical cancer with a focus on B and T cell immune aggregates, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLSs). Methods: Using multispectral imaging, we interrogated a cohort of patients with clinical stage I squamous or adenocarcinoma of the cervix with a focus on T and B cell spatial location and organization. Despite early-stage disease, recurrence was common at 37%, highlighting the need to identify patients at high risk for recurrence. Results: We demonstrated that high CD8+ T cell infiltration correlated significantly with improved overall survival (OS), particularly in patients with adenocarcinoma histology. CD8+ T cells colocalized with B cells, suggesting the formation of a more sophisticated cellular neighborhood, i.e., TLS, which has prognostic benefit in other solid tumors. CXCL13, a chemokine associated with TLS formation, correlated with improved recurrence-free survival. The combination of high CXCL13 and lymphoid structures correlated with improved OS. However, most immune structures in cervical cancer were lymphoid aggregates (LAs) that lack features of more developed TLS, such as high endothelial venules (HEVs) and germinal centers (GCs), highlighting a lack of full immune activation in this microenvironment. Validation in The Cancer Genome Atlas (TCGA) cohort illustrated similar trends in survival. Conclusions: Collectively, this work demonstrates the prognostic significance of immune infiltration and eventual TLS induction in early cervical cancer and presents potential future therapeutic targets.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary Table 1 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 2 A) Unmodified principal component analysis. B) WT1 MFI in CA-MSCs and nMSCs. The lower limit of CA-MSC WT1 MFI was used to classify hrMSCs. C) Proliferation assay (full time course) using ovarian cancer cells and shRNA knockdown MSCs. Scramble shRNA and tumor cells alone are shown. D) Tissue culture treated plates were coated with poly-D-lysine. This served as a positive control for adherence assays. FT190 control cells and OVSAHO tumor cells were utilized. P-values are shown. P-values were determined by Student’s T-test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 2 A) Unmodified principal component analysis. B) WT1 MFI in CA-MSCs and nMSCs. The lower limit of CA-MSC WT1 MFI was used to classify hrMSCs. C) Proliferation assay (full time course) using ovarian cancer cells and shRNA knockdown MSCs. Scramble shRNA and tumor cells alone are shown. D) Tissue culture treated plates were coated with poly-D-lysine. This served as a positive control for adherence assays. FT190 control cells and OVSAHO tumor cells were utilized. P-values are shown. P-values were determined by Student’s T-test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary data AMPK related DEG list
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supplementary data AMPK related DEG list
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 4 A) Representative images of organoids that were injected into NSG mice. FTE and MSCs were seeded at a 1:1 ratio under non-adherent conditions. FTE are labelled in red while hrMSCs are labelled in blue.B) Representative image of pancytokeratin IHC of tumor resulting from organoid implanted in vivo demonstrating human epithelial origin.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 4 A) Representative images of organoids that were injected into NSG mice. FTE and MSCs were seeded at a 1:1 ratio under non-adherent conditions. FTE are labelled in red while hrMSCs are labelled in blue.B) Representative image of pancytokeratin IHC of tumor resulting from organoid implanted in vivo demonstrating human epithelial origin.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 6 A) MDA adduct ELISA comparing nMSC and hrMSC conditioned media. Individual data points represent individual patient cell lines. Statistics were determined by the student’s T-test. B) Western blot validation of GW4969 effect on MSCs. Conditioned media was ultracentrifuged to remove large EVs (>500 µm) and exosomes (<500 µm). EV lysates were probed for CD36 expression. C) IF validation of EV transfer. MSCs were labelled with BODIPY C-12 and media was collected after an overnight incubation. Media was spun to remove debris and added to epithelial cells. Epithelial cells were screened for BODIPY positivity. D) MSCs were stained with BODIPY C-12, allowed to rest for 1hr, then media was removed, spun to remove debris, and added to FTE. FTE were analyzed by flow cytometry for BODIPY C-12 positivity. P-values are shown. P-values were determined by the student’s t-test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 6 A) MDA adduct ELISA comparing nMSC and hrMSC conditioned media. Individual data points represent individual patient cell lines. Statistics were determined by the student’s T-test. B) Western blot validation of GW4969 effect on MSCs. Conditioned media was ultracentrifuged to remove large EVs (>500 µm) and exosomes (<500 µm). EV lysates were probed for CD36 expression. C) IF validation of EV transfer. MSCs were labelled with BODIPY C-12 and media was collected after an overnight incubation. Media was spun to remove debris and added to epithelial cells. Epithelial cells were screened for BODIPY positivity. D) MSCs were stained with BODIPY C-12, allowed to rest for 1hr, then media was removed, spun to remove debris, and added to FTE. FTE were analyzed by flow cytometry for BODIPY C-12 positivity. P-values are shown. P-values were determined by the student’s t-test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 3 A/B/C) gH2AX and 53BP1 foci in cell trace deep red labelled MSCs. MSCs were co-cultured with FTE at a 1:1 ratio. D) Representative image of stromal regions that were chosen for 53BP1 foci validation in patient samples. Yellow X represents nMSCs while red X represents hrMSCs. E) Representative phenotype masking and 53BP1 stain in patient fallopian tubes. Foci were identified using ImageJ and are indicated as magenta foci in Fig. 3H. Cells that lacked clear foci, including cells without signal, were considered negative for 53BP1 foci. P-values are shown. P-values were determined by Student’s T-test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation
Supp. Figure 3 A/B/C) gH2AX and 53BP1 foci in cell trace deep red labelled MSCs. MSCs were co-cultured with FTE at a 1:1 ratio. D) Representative image of stromal regions that were chosen for 53BP1 foci validation in patient samples. Yellow X represents nMSCs while red X represents hrMSCs. E) Representative phenotype masking and 53BP1 stain in patient fallopian tubes. Foci were identified using ImageJ and are indicated as magenta foci in Fig. 3H. Cells that lacked clear foci, including cells without signal, were considered negative for 53BP1 foci. P-values are shown. P-values were determined by Student’s T-test.